Anticonvulsant Pharmacodynamics and Disposition of Triazolam in Rats††These results were presented, in part, at the Seventh Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, November 1992.
Authors:
- 1 September 1996
- journal article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 85 (9) , 999-1004
Abstract
Triazolam (TZ) is a triazolobenzodiazepine used in the treatment of insomnia that possesses significant anticonvulsant properties. Despite the widespread use of this drug, detailed pharmacokinetic-pharmacodynamic information is lacking, especially with respect to inhibition of seizure activity. TZ disposition has been described previously by methods with limited specificity, and the concentration-anticonvulsant effect relationship has not been characterized. The current studies were undertaken to examine TZ disposition with a specific HPLC method, and to evaluate the relationship between anticonvulsant effect and concentration in Sprague-Dawley rats. TZ pharmacokinetics were characterized after bolus or infusion administration; in a separate experiment, TZ pharmacodynamics were assessed with pentylenetetrazol-induced seizures. The systemic disposition of TZ could be described with a two-compartment model; systemic clearance ranged from 2.45 to 5.30 L/h/ kg, steady-state volume of distribution ranged from 2.10 to 4.02 L/kg, and mean residence time ranged from 47 to 65 min. The concentration-effect relationship was well described by a simple Emax model: Emax, expressed as the ratio of post-TZ to pre-TZ threshold convulsant doses of pentylenetetrazol, was 9.9 +/- 0.7, and the EC50 values were 10.0 +/- 4.6 ng/mL and 34.8 +/- 9.0 ng/g in serum and whole brain tissue, respectively. Under single-dose conditions, TZ is a very potent anticonvulsant in the rat pentylenetetrazol seizure model.Keywords
This publication has 30 references indexed in Scilit:
- Pharmacokinetics of the Newer BenzodiazepinesClinical Pharmacokinetics, 1989
- Disappointing results of increasing benzodiazepine dose after the development of anticonvulsant tolerance.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measureJournal of Pharmacokinetics and Biopharmaceutics, 1988
- Pharmacodynamics of Triazolam After Intravenous AdministrationThe Journal of Clinical Pharmacology, 1987
- Nighttime Dosing of Triazolam in Patients with Liver Disease and Normal Subjects: Kinetics and Daytime EffectsThe Journal of Clinical Pharmacology, 1987
- A timed intravenous pentylenetetrazol infusion scizure model for quantitating the anticonvulsant effect of valproic acid in the ratJournal of Pharmacological Methods, 1985
- The behavioural effects of Lorazepam are poorly related to its concentration in the brainLife Sciences, 1983
- BenzodiazepinesDrugs, 1980
- Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl- 4H-s-triazolo [4,3-a] [1,4] benzodiazepine, triazolam, a new central depressant. I. Absorption, distribution and excretion in rats, dogs and monkeysXenobiotica, 1979
- Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo [4,3-a] [1,4]benzodiazepine, triazolam, a new central depressant. II. Identification and determination of metabolites in rats and dogsXenobiotica, 1979